The ISCI and ISCBI will hold their annual joint face to face meeting at McGill University in Montreal 12th July 2026. To register please go to www.iscbi.org/events - Please register by 3 July 2026

 

Please Note: Access to the meeting cannot be guaranteed after the published deadline, but if you have missed registration please email admin@iscbi.org and you will be able to get access to a meeting report or recording. 

​

Event details

Start time: 9AM

​

08.30 Arrival

09.00 – 09.15 Welcome and ISCBI update, Glyn Stacey (ISCBI, UK)

09.15 - 10.45am ISCI session: chair Prof Ivana Barbaric (University of Sheffield, UK)

09:15 – 10:45 ISCI Session Chair: Prof Ivana Barbaric (University of Sheffield, UK)

• 09:15 – 09:30: Annual Progress Report: Overview of ISCI activities

• 09:30 – 09:45: Community Insights: Genetic Variant Assessment in hPSC-Derived Therapies

• 09:45 – 10:15: Translational Panel: From Bench to Bedside: Genetic Variants in hPSCs and the Path to Clinic-Ready Therapies;

Panellists: Dr Ricardo Baptista (SmartCella), Dr Terri Gaskell (RinRi), Dr Janet Rothberg (CCRM), Dr Anestis Tsakiridis (University of Sheffield)

• 10:15 – 10:45: Strategic Roadmap: Joint discussion on future priorities and collaborative milestones

10.45 - 11.15am refreshment break

11.15am - 12.00, ISCBI/ISCI session: An hPSC biobanking consensus for accurate genetic assignment of hPSC lines.

• Report on working group activity, Glyn Stacey

• Discussion on draft publication and agree timeline to complete

12.00pm – 12.45pm. ISCBI sessions, part 1: Next generation characterisation and quality control for hPSC biobanks.

12.00pm – 12.45pm. ISCBI session, part 1: Chair Prof Jung-hyun Kim (Ajou University, Korea),

Introductory comments including:

Dr Changpyo Hong, Genetic analysis expert, YipCell, Seoul, Korea. Regulatory-industry experience in the application of genetic characterisation.

Dr Ji-Yoon Lee (KNIH, Korea). Experiences with ‘omics’ analysis for clinical application at the KNIH hPSC bank.

Comments from other attendees about the challenges of new technologies for clinical translation.

Open discussion part 1: Horizon scanning

What are the new and emerging technologies in stem cell characterisation and QC?

• Genome and epigenome

• Phenotype

• Functionality: Pluripotency and differentiation capacity

12.45– 13.30pm buffet lunch

13.30 – 14.45pm. ISCBI session part 2:

Open discussion part 2: What are the key considerations in qualifying and implementing new technologies?

• Setting data output acceptance criteria (e.g. GCCP 2.0) to ease path in product release

• Considerations regarding software, analytical algorithms and data management.

• Identification of aspects of biobanking and QC procedures where more detailed guidance is needed.

14.45 – 15.30 Conclusions/forward actions from session chairs

15.30 Concluding remarks and close, Glyn Stacey (ISCBI)                              

​